or Try an Advanced Search...

    Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia Stocks List

    Symbol Grade Name % Change
    CRBU F Caribou Biosciences, Inc. -1.53
    MBRX F Moleculin Biotech, Inc. 2.80
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Medicine Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia Antineoplastic Drugs Biopharmaceutical Biotechnology Blastoma Breakthrough Therapy CD19 Cancer Cancer Immunotherapy Cell Biology Cell Therapy Chemotherapy Chimeric Antigen Receptor T Cell Clinical Medicine Glioblastoma Hematologic Malignancies Leukemia Multiple Myeloma

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia stocks.

    Symbol Grade Name Weight
    CNCR D Loncar Cancer Immunotherapy ETF 1.01
    WDNA D WisdomTree BioRevolution Fund 0.98
    GNOM D Global X Genomics & Biotechnology ETF 0.61
    BBC D Virtus LifeSci Biotech Clinical Trials ETF 0.54
    IDNA D iShares Genomics Immunology and Healthcare ETF 0.4
    View all Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia ETFs...
    Compare ETFs
    Compare CNCR to GNOM Compare CNCR to IDNA Compare GNOM to BBC

        Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia Stocks Recent News

        Date Stock Title
        Apr 18 CRBU Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value
        Apr 18 MBRX Moleculin's acute myeloid leukemia treatment gets EMA's orphan drug designation
        Apr 18 MBRX European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
        Apr 15 CRBU Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
        Related Industries: Biotechnology
        Related Stock Lists: Medicine Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia Antineoplastic Drugs Biopharmaceutical Biotechnology Blastoma Breakthrough Therapy CD19 Cancer Cancer Immunotherapy Cell Biology Cell Therapy Chemotherapy Chimeric Antigen Receptor T Cell Clinical Medicine Glioblastoma Hematologic Malignancies Leukemia Multiple Myeloma
        Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia

        Treatment of relapsed or refractory acute myeloid leukemia (AML) typically involves a combination of chemotherapy, targeted therapy, and stem cell transplantation. Chemotherapy is the mainstay of treatment and may include drugs such as cytarabine, daunorubicin, and idarubicin. Targeted therapies, such as FLT3 inhibitors, may also be used. Stem cell transplantation is often recommended for patients with relapsed or refractory AML, as it can provide a potentially curative option.

        Browse All Tags